Gilead Sciences Stock Price, News & Analysis (NASDAQ:GILD)

$80.91 +1.51 (+1.90 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$80.91
Today's Range$79.29 - $80.94
52-Week Range$63.76 - $89.54
Volume5.43 million shs
Average Volume9.94 million shs
Market Capitalization$107.67 billion
P/E Ratio10.54
Dividend Yield2.82%

About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs


Debt-to-Equity Ratio1.10%
Current Ratio3.55%
Quick Ratio3.48%


Trailing P/E Ratio10.53515625
Forward P/E Ratio12.97
P/E Growth-1.85

Sales & Book Value

Annual Sales$26.11 billion
Price / Sales4.05
Cash Flow$12.62 per share
Price / Cash6.41
Book Value$15.69 per share
Price / Book5.16


Trailing EPS$7.68
Net Income$4.63 billion
Net Margins17.73%
Return on Equity50.29%
Return on Assets17.85%


Outstanding Shares1,306,270,000

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Tuesday, February 6th. Stockholders of record on Friday, March 16th will be given a dividend of $0.57 per share on Thursday, March 29th. This represents a $2.28 annualized dividend and a dividend yield of 2.82%. The ex-dividend date is Thursday, March 15th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.52. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings data on Tuesday, February, 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.67 by $0.11. The biopharmaceutical company earned $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm's revenue for the quarter was down 18.7% compared to the same quarter last year. During the same period last year, the firm posted $2.70 EPS. View Gilead Sciences' Earnings History.

When will Gilead Sciences make its next earnings announcement?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Gilead Sciences.

Where is Gilead Sciences' stock going? Where will Gilead Sciences' stock price be in 2018?

27 Wall Street analysts have issued 1-year target prices for Gilead Sciences' stock. Their forecasts range from $68.00 to $105.00. On average, they anticipate Gilead Sciences' stock price to reach $87.54 in the next year. View Analyst Ratings for Gilead Sciences.

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

  • 1. Leerink Swann analysts commented, "RARE’s 4Q report this afternoon was relatively in line with expectations. Incremental clinical updates for burosumab in young children and in adults with osteomalacia (bone softening) in the report further support the drug’s utility in both populations. The year ahead is shaping up to be catalyst-rich for RARE, with data from two gene therapy programs, the Phase 3 of trihep in Glut1 DS, and a decision on trihep registration plans in FAOD expected over the coming months. Although we continue to expect a slow rollout of burosumab (PDUFA date 4/17/18) and Mepsevii, we see opportunity for further upside in shares over the course of 2018. Maintain OW." (2/22/2018)
  • 2. BMO Capital Markets analysts commented, "Early biopotency signals from a single patient dosed with ABO-101 (for Sanfilippo B), demonstrate targeted reduction on toxic sugars." (2/7/2018)
  • 3. According to Zacks Investment Research, "Gilead’s HCV franchise is under tremendous pressure due to lower patient starts and increasing competition. Higher discounts and payer mix continue to hurt sales. Sales are expected to decline further. Moreover, Gilead has lost exclusivity for Viread and Truvada. Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the United States and EU. The TAF-based regimens now represent 56% of total Gilead HIV prescription volume following the launch of Genvoya and the launches of Odefsey and Descovy in 2016. However, Gilead also faces competition from generic HIV products which should impact sales. Nevertheless, the acquisition of Kite and the subsequent approval of Yescarta bodes well for Gilead given the potential in the CAR T therapy. Shares of the company have outperformed the industry in the last six months." (1/18/2018)
  • 4. Maxim Group analysts commented, "We returned from Beijing, China and listened as Tim Moore, EVP of Technical Operations and the CEO of Fosun Kite Biotechnology co. (Richard Wang) presented manufacturing plans for the launch of Yescarta, and the opportunity in China (see the slides in the pages that follow). Suffice to say, we were impressed and left clear with the notion that Gilead (and Kite) can overcome manufacturing challenges to commercialize in the U.S. and globally, especially China, this new innovative therapy. As a result, we are upgrading Gilead to Buy, from Hold and establishing a $94 price target." (11/30/2017)

Are investors shorting Gilead Sciences?

Gilead Sciences saw a increase in short interest in the month of January. As of January 12th, there was short interest totalling 21,804,384 shares, an increase of 21.3% from the December 29th total of 17,982,136 shares. Based on an average daily trading volume, of 8,065,879 shares, the short-interest ratio is currently 2.7 days. Currently, 1.7% of the shares of the company are short sold.

Who are some of Gilead Sciences' key competitors?

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:

  • John C. Martin Ph.D., Chairman of the Board (Age 65)
  • John F. Milligan Ph.D., President, Chief Executive Officer, Director (Age 55)
  • Robin L. Washington, Chief Financial Officer, Executive Vice President (Age 54)
  • Kevin B. Young, Chief Operating Officer (Age 59)
  • Norbert W. Bischofberger Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer (Age 61)
  • Gregg H. Alton, Executive Vice President - Corporate and Medical Affairs (Age 51)
  • John F. Cogan Jr. Ph.D., Lead Independent Director (Age 69)
  • Jacqueline K. Barton, Director (Age 64)
  • Kelly A. Kramer, Independent Director (Age 49)
  • Kevin E. Lofton, Independent Director (Age 62)

Who owns Gilead Sciences stock?

Gilead Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.95%), Bank of New York Mellon Corp (2.34%), Parnassus Investments CA (1.47%), Geode Capital Management LLC (1.21%), Franklin Resources Inc. (1.06%) and Sanders Capital LLC (0.76%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Who sold Gilead Sciences stock? Who is selling Gilead Sciences stock?

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Renaissance Technologies LLC, Boston Partners, Two Sigma Advisers LP, Credit Agricole S A, AXA, Bessemer Group Inc. and OppenheimerFunds Inc.. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Who bought Gilead Sciences stock? Who is buying Gilead Sciences stock?

Gilead Sciences' stock was acquired by a variety of institutional investors in the last quarter, including Sanders Capital LLC, CI Global Investments Inc., Amundi Pioneer Asset Management Inc., Arrowstreet Capital Limited Partnership, BlackRock Inc., CI Investments Inc., Russell Investments Group Ltd. and LSV Asset Management. View Insider Buying and Selling for Gilead Sciences.

How do I buy Gilead Sciences stock?

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of Gilead Sciences stock can currently be purchased for approximately $80.91.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $107.67 billion and generates $26.11 billion in revenue each year. The biopharmaceutical company earns $4.63 billion in net income (profit) each year or $7.68 on an earnings per share basis. Gilead Sciences employs 9,000 workers across the globe.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DR, FOSTER CITY, CA 94404, United States. The biopharmaceutical company can be reached via phone at +1-650-5743000 or via email at [email protected]

MarketBeat Community Rating for Gilead Sciences (GILD)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  1,673 (Vote Outperform)
Underperform Votes:  627 (Vote Underperform)
Total Votes:  2,300
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Gilead Sciences (NASDAQ:GILD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.632.592.592.64
Ratings Breakdown: 0 Sell Rating(s)
10 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $87.54$85.99$85.17$80.75
Price Target Upside: 8.48% upside8.82% upside15.46% upside8.11% upside

Gilead Sciences (NASDAQ:GILD) Consensus Price Target History

Price Target History for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2018Leerink SwannReiterated RatingMkt Perform -> Market Perform$83.00 -> $80.00LowView Rating Details
2/12/2018MizuhoReiterated RatingBuy -> Buy$83.00 -> $95.00LowView Rating Details
2/8/2018BMO Capital MarketsBoost Price TargetOutperform -> Market Perform$86.00 -> $88.00HighView Rating Details
2/7/2018Credit Suisse GroupSet Price TargetHold$80.00HighView Rating Details
2/8/2018CitigroupReiterated RatingBuy -> Buy$103.00 -> $105.00HighView Rating Details
2/7/2018Morgan StanleyLower Price TargetEqual Weight -> Equal Weight$87.00 -> $84.00MediumView Rating Details
2/7/2018Bank of AmericaBoost Price TargetNeutral -> Neutral$82.00 -> $87.00MediumView Rating Details
2/6/2018Maxim GroupSet Price TargetBuy$94.00HighView Rating Details
1/26/2018Jefferies GroupUpgradeHold -> Buy$81.19 -> $93.00HighView Rating Details
1/16/2018Wells Fargo & CoUpgradeMarket Perform -> Outperform$79.02 -> $96.00LowView Rating Details
12/21/2017OppenheimerReiterated RatingHoldMediumView Rating Details
11/13/2017ArgusDowngradeBuy -> Hold$73.25 -> $73.77N/AView Rating Details
10/25/2017JPMorgan Chase & Co.Set Price TargetBuy$85.00N/AView Rating Details
10/19/2017William BlairReiterated RatingBuyN/AView Rating Details
10/19/2017Berenberg BankSet Price TargetBuy$96.00N/AView Rating Details
10/11/2017BarclaysReiterated RatingOverweight -> Overweight$90.00N/AView Rating Details
10/5/2017CIBCInitiated CoverageMarket Perform -> Market PerformN/AView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$94.00LowView Rating Details
8/31/2017CowenReiterated RatingOutperform$90.00MediumView Rating Details
8/31/2017Deutsche BankReiterated RatingBuy$81.00MediumView Rating Details
8/28/2017Needham & Company LLCReiterated RatingHoldLowView Rating Details
8/29/2017Robert W. BairdReiterated RatingOutperform$87.00LowView Rating Details
7/26/2017Redburn PartnersInitiated CoverageBuyMediumView Rating Details
5/3/2017GabelliReiterated RatingBuy$85.00MediumView Rating Details
5/3/2017Stifel NicolausReiterated RatingBuy$87.00MediumView Rating Details
4/21/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
3/13/2017Goldman Sachs GroupReiterated RatingNeutral$70.00 -> $68.00LowView Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00N/AView Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyN/AView Rating Details
(Data available from 2/24/2016 forward)


Gilead Sciences (NASDAQ:GILD) Earnings History and Estimates Chart

Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ GILD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/30/2018$1.64N/AView Earnings Details
2/6/2018Q4 2017$1.67$1.78$5.71 billion$5.95 billionViewListenView Earnings Details
10/26/2017Q3 2017$2.13$2.27$6.40 billion$6.51 billionViewN/AView Earnings Details
7/26/2017Q2 2017$2.11$2.56$6.35 billion$7.14 billionViewN/AView Earnings Details
5/2/2017Q1 2017$2.18$2.20$6.66 billion$6.51 billionViewListenView Earnings Details
2/7/2017Q416$2.61$2.70$7.16 billion$7.30 billionViewListenView Earnings Details
11/1/2016Q316$2.87$2.75$7.47 billion$7.40 billionViewListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details
4/30/2015Q115$2.78$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.27$2.43$6.68 million$7.31 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.61$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.75$1.48$3.80 billion$5.00 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
7/26/2011Q2 2011$0.48$0.47ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
10/19/2010Q3 2010$0.42$0.43ViewN/AView Earnings Details
7/20/2010Q2 2010$0.41$0.40ViewN/AView Earnings Details
4/20/2010Q1 2010$0.46$0.47ViewN/AView Earnings Details
1/26/2010Q4 2009$0.41$0.45ViewN/AView Earnings Details
10/20/2009Q3 2009$0.35$0.37ViewN/AView Earnings Details
7/21/2009Q2 2009$0.31$0.33ViewN/AView Earnings Details
4/21/2009Q1 2009$0.30$0.32ViewN/AView Earnings Details
1/27/2009Q4 2008$0.28$0.30ViewN/AView Earnings Details
10/16/2008Q3 2008$0.25$0.26ViewN/AView Earnings Details
7/17/2008Q2 2008$0.25$0.23ViewN/AView Earnings Details
4/16/2008Q1 2008$0.24$0.26ViewN/AView Earnings Details
1/23/2008Q4 2007$0.21$0.21ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Gilead Sciences (NASDAQ:GILD) Earnings Estimates

2018 EPS Consensus Estimate: $6.48
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$1.55$1.78$1.67
Q2 20183$1.46$1.76$1.61
Q3 20183$1.38$1.74$1.56
Q4 20183$1.31$1.88$1.64
(Earnings estimates data provided by Zacks Investment Research)


Gilead Sciences (NASDAQ:GILD) Dividend Information

Next Dividend:3/29/2018
Annual Dividend:$2.08
Dividend Yield:2.57%
Payout Ratio:27.08% (Trailing 12 Months of Earnings)
33.33% (Based on This Year's Estimates)
34.61% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Gilead Sciences (NASDAQ GILD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 75.71%
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ GILD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/20/2018Gregg H AltonEVPSell14,435$81.54$1,177,029.90View SEC Filing  
2/9/2018Gayle E WilsonDirectorSell60,000$77.92$4,675,200.00182,258View SEC Filing  
2/1/2018Gregg H AltonEVPSell25,000$83.51$2,087,750.0062,738View SEC Filing  
2/1/2018John C MartinChairmanSell50,000$83.56$4,178,000.003,046,766View SEC Filing  
1/16/2018James R MeyersEVPSell100,000$80.24$8,024,000.00102,715View SEC Filing  
1/11/2018Gregg H AltonEVPSell30,000$79.00$2,370,000.0057,114View SEC Filing  
1/2/2018Gregg H AltonEVPSell15,000$73.87$1,108,050.0064,613View SEC Filing  
1/2/2018John C MartinInsiderSell50,000$73.62$3,681,000.003,046,766View SEC Filing  
12/1/2017Gregg H AltonEVPSell15,000$74.64$1,119,600.0070,988View SEC Filing  
12/1/2017John C MartinInsiderSell73,333$74.98$5,498,508.343,070,099View SEC Filing  
11/13/2017John F MilliganInsiderSell220,000$72.88$16,033,600.00View SEC Filing  
11/1/2017Gregg H AltonEVPSell15,000$74.82$1,122,300.0077,363View SEC Filing  
11/1/2017John C MartinInsiderSell73,333$75.13$5,509,508.293,070,099View SEC Filing  
10/2/2017Gregg H AltonEVPSell25,000$82.65$2,066,250.00View SEC Filing  
10/2/2017John C MartinInsiderSell73,333$82.56$6,054,372.48View SEC Filing  
9/7/2017Robin L WashingtonCFOSell51,820$85.00$4,404,700.0043,352View SEC Filing  
9/1/2017Gregg H AltonEVPSell25,000$83.05$2,076,250.00101,488View SEC Filing  
9/1/2017John C MartinInsiderSell73,333$83.11$6,094,705.632,996,766View SEC Filing  
8/31/2017James R MeyersEVPSell60,000$83.19$4,991,400.0062,715View SEC Filing  
8/30/2017Gregg H AltonEVPSell50,000$79.00$3,950,000.00113,237View SEC Filing  
8/1/2017Gregg H AltonEVPSell15,000$75.88$1,138,200.00106,113View SEC Filing  
8/1/2017John C MartinInsiderSell73,333$75.86$5,563,041.383,199,969View SEC Filing  
7/21/2017Gregg H AltonEVPSell40,000$74.00$2,960,000.00137,488View SEC Filing  
7/3/2017Gregg H AltonEVPSell5,000$71.06$355,300.00102,988View SEC Filing  
7/3/2017John C MartinInsiderSell73,333$71.00$5,206,643.003,199,969View SEC Filing  
5/9/2017John Francis CoganDirectorSell9,943$67.25$668,666.7547,562View SEC Filing  
4/3/2017John C MartinInsiderSell73,333$67.18$4,926,510.943,199,969View SEC Filing  
3/30/2017Gregg H AltonEVPSell5,000$67.48$337,400.00117,988View SEC Filing  
1/3/2017John C MartinInsiderSell73,337$73.59$5,396,869.833,204,433View SEC Filing  
11/18/2016John W MadiganDirectorSell105,000$74.86$7,860,300.00121,761View SEC Filing  
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.003,231,096View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00132,964View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.001,128,963View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.003,287,810View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.004,119,727View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.0064,122View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.001,170,963View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.004,119,727View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.0063,122View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.001,170,963View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.0063,122View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.004,119,727View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.001,170,963View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.0062,939View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00177,964View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.001,170,963View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.004,119,727View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.0063,122View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00147,090View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50110,523View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.003,948,066View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.0048,783View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.003,948,066View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.0048,783View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00127,936View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.001,029,108View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.0044,309View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00131,422View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.003,948,066View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.0044,309View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00133,422View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.0044,309View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00165,168View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.001,029,108View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00133,422View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.003,948,066View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.0048,783View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00135,422View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.0044,309View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.001,029,108View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.003,948,066View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00101,769View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.213,948,066View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00119,302View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.0049,832View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00130,694View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.504,429,387View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.0012,778View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.0049,832View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00119,302View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.0039,542View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.8428,562View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00132,694View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.504,429,387View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.0039,542View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00119,302View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.9628,562View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.0084,484View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.504,257,235View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00216,418View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.0032,938View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.002,159,643View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00161,840View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.002,159,643View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.0046,938View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.744,057,121View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.002,159,643View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Gilead Sciences (NASDAQ GILD) News Headlines

How Gilead Sciences Is Betting Big on Gene EditingHow Gilead Sciences Is Betting Big on Gene Editing - February 23 at 9:33 PM
Gileads Latest Deal Is Good News for BiotechsGilead's Latest Deal Is Good News for Biotechs - February 23 at 3:06 PM
How Johnson & Johnson’s Infectious Diseases Portfolio Perform in 2017How Johnson & Johnson’s Infectious Diseases Portfolio Perform in 2017 - February 23 at 3:06 PM
Gilead Sciences Announces Senior Management ChangeGilead Sciences Announces Senior Management Change - February 23 at 5:10 AM
Sangamo Therapeutics: Great Start To 2018 - $3 Billion KITE Announcement - Seeking AlphaSangamo Therapeutics: Great Start To 2018 - $3 Billion KITE Announcement - Seeking Alpha - February 22 at 3:13 PM
Leerink Swann Lowers Gilead Sciences (GILD) Price Target to $80.00Leerink Swann Lowers Gilead Sciences (GILD) Price Target to $80.00 - February 22 at 11:16 AM
5 Drugs That Are Critical for Gilead Sciences Future5 Drugs That Are Critical for Gilead Sciences' Future - February 22 at 8:13 AM
Gilead Sciences, Inc. (GILD) EVP Gregg H. Alton Sells 14,435 SharesGilead Sciences, Inc. (GILD) EVP Gregg H. Alton Sells 14,435 Shares - February 21 at 9:06 PM
$5.37 Billion in Sales Expected for Gilead Sciences, Inc. (GILD) This Quarter$5.37 Billion in Sales Expected for Gilead Sciences, Inc. (GILD) This Quarter - February 21 at 5:58 AM
Merck shares dip after surprise patent loss to Gilead - MarketWatchMerck shares dip after surprise patent loss to Gilead - MarketWatch - February 20 at 3:06 PM
Merck Falls After $2.54 Billion Gilead Verdict Is TossedMerck Falls After $2.54 Billion Gilead Verdict Is Tossed - February 20 at 3:06 PM
US Stocks Lower TuesdayUS Stocks Lower Tuesday - February 20 at 3:06 PM
Merck shares dip after surprise patent loss to GileadMerck shares dip after surprise patent loss to Gilead - February 20 at 3:06 PM
The search for value playsThe search for value plays - February 20 at 3:06 PM
Merck Shares Fall After Judge Tosses $2.54 Billion Gilead VerdictMerck Shares Fall After Judge Tosses $2.54 Billion Gilead Verdict - February 20 at 3:06 PM
Gilead Sciences, Inc. (GILD) Given Average Rating of "Buy" by BrokeragesGilead Sciences, Inc. (GILD) Given Average Rating of "Buy" by Brokerages - February 20 at 12:02 PM
Gilead Sciences (GILD) Price Target Lowered to $84.00 at Morgan StanleyGilead Sciences (GILD) Price Target Lowered to $84.00 at Morgan Stanley - February 19 at 10:12 PM
Gilead Sciences (GILD) Price Target Increased to $87.00 by Analysts at Bank of AmericaGilead Sciences (GILD) Price Target Increased to $87.00 by Analysts at Bank of America - February 19 at 10:12 PM
Gilead Sciences (GILD) Given New $83.00 Price Target at Leerink SwannGilead Sciences (GILD) Given New $83.00 Price Target at Leerink Swann - February 19 at 9:08 PM
Gilead Sciences (GILD) Rating Increased to Strong-Buy at VetrGilead Sciences (GILD) Rating Increased to Strong-Buy at Vetr - February 19 at 7:28 PM
Kymriah May Emerge as a Robust Treatment Option in DLBCL IndicationKymriah May Emerge as a Robust Treatment Option in DLBCL Indication - February 19 at 3:04 PM
Gilead Sciences (GILD) Raised to "Strong-Buy" at VetrGilead Sciences (GILD) Raised to "Strong-Buy" at Vetr - February 19 at 12:18 PM
Gilead Sciences, Inc. (GILD) Expected to Announce Earnings of $1.61 Per ShareGilead Sciences, Inc. (GILD) Expected to Announce Earnings of $1.61 Per Share - February 19 at 12:14 PM
Gilead wins big reversal of patent verdict - Gilead Sciences, Inc ... - Seeking AlphaGilead wins big reversal of patent verdict - Gilead Sciences, Inc ... - Seeking Alpha - February 18 at 3:04 PM
Should You Be Concerned About Gilead Sciences Inc’s (NASDAQ:GILD) -65.72% Earnings Decline?Should You Be Concerned About Gilead Sciences Inc’s (NASDAQ:GILD) -65.72% Earnings Decline? - February 17 at 5:12 AM
Why 2018 Could Be An Explosive Year For Biotech MergersWhy 2018 Could Be An Explosive Year For Biotech Mergers - February 16 at 3:10 PM
Today’s Research Reports on Trending Tickers: Gilead Sciences and Abbott LaboratoriesToday’s Research Reports on Trending Tickers: Gilead Sciences and Abbott Laboratories - February 15 at 3:10 PM
3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate - February 15 at 6:36 AM
Gilead Sciences, Inc. (GILD) Director Gayle E. Wilson Sells 60,000 SharesGilead Sciences, Inc. (GILD) Director Gayle E. Wilson Sells 60,000 Shares - February 13 at 6:10 PM
Gilead Sciences (GILD) Receives Buy Rating from MizuhoGilead Sciences (GILD) Receives Buy Rating from Mizuho - February 12 at 11:52 PM
Today’s Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Gilead SciencesToday’s Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Gilead Sciences - February 12 at 3:07 PM
Q4 2018 EPS Estimates for Gilead Sciences, Inc. Raised by William Blair (GILD)Q4 2018 EPS Estimates for Gilead Sciences, Inc. Raised by William Blair (GILD) - February 12 at 7:40 AM
How Huge Is the Latest HIV Drug Approval for Gilead Sciences?How Huge Is the Latest HIV Drug Approval for Gilead Sciences? - February 12 at 7:26 AM
Gilead Sciences, Inc. Forecasted to Earn Q1 2018 Earnings of $1.68 Per Share (GILD)Gilead Sciences, Inc. Forecasted to Earn Q1 2018 Earnings of $1.68 Per Share (GILD) - February 12 at 2:34 AM
Gilead Sciences (GILD) Upgraded to Strong-Buy at ValuEngineGilead Sciences (GILD) Upgraded to Strong-Buy at ValuEngine - February 11 at 10:52 PM
Gilead Sciences (GILD) Buy Rating Reiterated at CitigroupGilead Sciences' (GILD) Buy Rating Reiterated at Citigroup - February 11 at 10:56 AM
Gilead Sciences (GILD) Downgraded by TheStreetGilead Sciences (GILD) Downgraded by TheStreet - February 11 at 10:56 AM
Does Gilead Stand A Chance After Its Q4 Earnings? - Seeking Alpha - Seeking AlphaDoes Gilead Stand A Chance After Its Q4 Earnings? - Seeking Alpha - Seeking Alpha - February 9 at 5:12 AM
Gilead Sciences to Present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21Gilead Sciences to Present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21 - February 9 at 5:12 AM
Stock Market Drop Not Seen Dampening Healthcare Deal ActivityStock Market Drop Not Seen Dampening Healthcare Deal Activity - February 9 at 5:12 AM
Credit Suisse Group Reiterates "$80.00" Price Target for Gilead Sciences (GILD)Credit Suisse Group Reiterates "$80.00" Price Target for Gilead Sciences (GILD) - February 8 at 7:48 PM
FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up - NasdaqFDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up - Nasdaq - February 8 at 3:10 PM
Inside Valeant Pharmaceuticals’ Recent DivestmentsInside Valeant Pharmaceuticals’ Recent Divestments - February 8 at 3:10 PM
Gilead Sciences (GILD) Price Target Raised to $88.00Gilead Sciences (GILD) Price Target Raised to $88.00 - February 8 at 12:09 PM
Gileads once-a-day HIV regimen has been approved by FDA - MarketWatchGilead's once-a-day HIV regimen has been approved by FDA - MarketWatch - February 8 at 8:01 AM
Wired News – Actinium Pharma Reported Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML PatientsWired News – Actinium Pharma Reported Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients - February 8 at 8:01 AM
Here's What Gilead Sciences Just Said About Its FutureHere's What Gilead Sciences Just Said About Its Future - February 8 at 8:01 AM
Is Gilead Sciences, Inc. Stock Still a Solid Value Play?Is Gilead Sciences, Inc. Stock Still a Solid Value Play? - February 8 at 7:10 AM
Gilead Sciences (GILD) "Hold" Rating Reiterated at BMO Capital MarketsGilead Sciences' (GILD) "Hold" Rating Reiterated at BMO Capital Markets - February 8 at 12:14 AM
GILDs Sales Wane, SGMO Safe With CHAMPIONS, Alls Not Well With Veterinarians? - NasdaqGILD's Sales Wane, SGMO Safe With CHAMPIONS, All's Not Well With Veterinarians? - Nasdaq - February 7 at 3:09 PM

SEC Filings

Gilead Sciences (NASDAQ:GILD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Gilead Sciences (NASDAQ:GILD) Income Statement, Balance Sheet and Cash Flow Statement


Gilead Sciences (NASDAQ GILD) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.